KLRK1 and cancer: A representative example of this disparity is shown in Fig. 1b, where 18 % of the cancer patient’s CD3+CD4+ T cells are positive for NKG2D (lower panel), while only 1.4 % of the healthy control’s CD3+CD4+ T cells show this staining (upper panel).